Skip to content
Med Rx.

Bromfenac Sodium interactions

Checked as Bromfenac in this data source.

Full monograph for Bromfenac SodiumCheck it against another medicine

Medicines

270 documented

Severity

Mechanism

Medicines documented to interact with Bromfenac Sodium, worst severity first.
MedicineSeverityMechanismEffectSources
AcalabrutinibMajorSynergyCoadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.3 sources — open the full entry
Adefovir DipivoxilMajorExcretionCoadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…1 sources — open the full entry
ApixabanMajorSynergyConcomitant use of apixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation…39 sources — open the full entry
BetrixabanMajorSynergyConcomitant use of betrixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation…39 sources — open the full entry
CabozantinibMajorSynergyCoadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment…39 sources — open the full entry
Dabigatran Etexilate MesylateMajorSynergyCoadministration of thrombin inhibitors with drugs that affect platelet function may potentiate the risk of bleeding due to additive or synergistic effects on…2 sources — open the full entry
Dalteparin SodiumMajorSynergyIn patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during low molecular weight heparin (LMWH)…12 sources — open the full entry
DasatinibMajorSynergyCoadministration of dasatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with…5 sources — open the full entry
DeferasiroxMajorSynergyCoadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal bleeding associated with the use of deferasirox…3 sources — open the full entry
Enoxaparin SodiumMajorSynergyIn patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during low molecular weight heparin (LMWH)…12 sources — open the full entry
EverolimusMajorSynergyCoadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive…4 sources — open the full entry
Fondaparinux SodiumMajorSynergyIn patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux…1 sources — open the full entry
Human Anti-D ImmunoglobulinsMajorSynergyCoadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available…11 sources — open the full entry
IbrutinibMajorSynergyCoadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.6 sources — open the full entry
IodixanolMajorSynergyConcomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal…7 sources — open the full entry
IohexolMajorSynergyConcomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal…7 sources — open the full entry
IopamidolMajorSynergyConcomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal…7 sources — open the full entry
Ketorolac TromethamineMajorSynergyThe use of ketorolac in combination with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious adverse effects such as renal…1 sources — open the full entry
LeflunomideMajorSynergyThe recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity…3 sources — open the full entry
Lithium CarbonateMajorExcretionCoadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase serum lithium levels and induce toxicity in some patients. The exact mechanism…48 sources — open the full entry
MethotrexateMajorExcretionCoadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed…30 sources — open the full entry
Monobasic Sodium Phosphate + Dibasic Sodium PhosphateMajorOthersThe following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing. It does not apply to products containing…3 sources — open the full entry
Ponatinib HydrochlorideMajorSynergyCoadministration of ponatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with…3 sources — open the full entry
Prasugrel HydrochlorideMajorSynergyConcomitant use of prasugrel with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents…2 sources — open the full entry
RamucirumabMajorSynergyTheoretical concerns exist that nonsteroid anti-inflammatory drugs (NSAIDs) and salicylates may potentiate the risk of bleeding and gastrointestinal…1 sources — open the full entry
Regorafenib MonohydrateMajorSynergyCoadministration of regorafenib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment…5 sources — open the full entry
RivaroxabanMajorSynergyConcomitant use of rivaroxaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation…1 sources — open the full entry
Tacrolimus MonohydrateOralTopicalMajorSynergyCoadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive…4 sources — open the full entry
Tenofovir AlafenamideMajorExcretionCoadministration of tenofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Additionally…8 sources — open the full entry
Tenofovir DisoproxilMajorExcretionCoadministration of tenofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Additionally…8 sources — open the full entry
Warfarin SodiumMajorSynergyNonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the hypoprothrombinemic effect and bleeding risk associated with oral anticoagulants.72 sources — open the full entry
Acyclovir + HydrocortisoneModerateSynergyThe combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity…11 sources — open the full entry
Alendronic acidModerateSynergyTheoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates…12 sources — open the full entry
Alendronic Acid + Vitamin D3ModerateSynergyTheoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates…12 sources — open the full entry
Allium cepa + Heparin + AllantoinModerateSynergyTheoretically, the coadministration of nonsteroidal anti-inflammatory drugs (NSAIDs) and heparin or low molecular weight heparin (LMWH) may potentiate the risk…6 sources — open the full entry
AlteplaseModerateSynergySystemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with…3 sources — open the full entry
AmikacinModerateSynergyThe nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in…6 sources — open the full entry
Amlodipine BesilateModerateAntagonismLimited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…41 sources — open the full entry
Amlodipine Besilate + AtenololModerateAntagonismLimited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms51 sources — open the full entry
Amlodipine Besilate + AtorvastatinModerateAntagonismLimited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…41 sources — open the full entry
Amlodipine Besilate + Benazepril HydrochlorideModerateAntagonismLimited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms57 sources — open the full entry
Amlodipine Besilate + Olmesartan MedoxomilModerateAntagonismLimited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms47 sources — open the full entry
Amlodipine Besilate + TelmisartanModerateAntagonismLimited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms47 sources — open the full entry
Amlodipine Besilate + ValsartanModerateAntagonismLimited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms47 sources — open the full entry
AspirinModerateSynergyThe combined use of low-dose or high-dose aspirin with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious…26 sources — open the full entry
Aspirin + DipyridamoleModerateSynergyThe combined use of low-dose or high-dose aspirin with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious…2 documented mechanisms29 sources — open the full entry
AtenololModerateAntagonismNonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of…10 sources — open the full entry
Atenolol + ChlorthalidoneModerateAntagonismNonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of…2 documented mechanisms36 sources — open the full entry
Azilsartan MedoxomilModerateAntagonismNonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is…2 documented mechanisms10 sources — open the full entry
Azilsartan Medoxomil + ChlorthalidoneModerateAntagonismConcomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal…3 documented mechanisms36 sources — open the full entry

Therapeutic duplication

Drug classes that overlap with Bromfenac Sodium, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.